Ozempic and Gambling: What We Know, What We Don't, and Why Researchers Are Watching

Charlie Wallace still goes to the Encore Boston Harbor casino with his husband and friends. But since starting Wegovy, he reports little desire to actually play the slots. His story, covered by the Boston Globe in February 2025, is one of a growing number of anecdotal reports from GLP-1 medication users who say their compulsive behaviors — gambling, online shopping, nail-biting, skin-picking — have quieted alongside their appetite.

The reports are striking. They are also, at this point, entirely unproven. Here's an honest assessment of where the evidence stands.

The Evidence Scale: Where Gambling Falls

That's the uncomfortable truth. Gambling and compulsive behavior are at the very bottom of the evidence hierarchy for GLP-1 medications. There are no clinical trials, no observational studies, no registry analyses, and no preclinical animal models studying GLP-1 agonists and gambling specifically. What exists is a growing pile of individual reports — compelling, consistent, but scientifically insufficient on their own.

What People Are Reporting

The anecdotal reports follow a consistent pattern. People who start GLP-1 medications for weight loss or diabetes describe a generalized dampening of compulsive urges that extends beyond food. The most commonly reported non-food behavioral changes include reduced gambling urges, diminished online shopping compulsions, decreased alcohol consumption, and lowered interest in various repetitive or reward-seeking behaviors.

Dr. Anna Lembke, chief of the Stanford Addiction Medicine Dual Diagnosis Clinic and author of Dopamine Nation, has been openly discussing this phenomenon. In a Stanford Medicine feature from April 2025, she acknowledged the early promise while cautioning that anecdotal evidence, no matter how numerous, doesn't constitute proof.

A March-April 2025 review article in the Missouri Medicine journal proposed the term "anti-consumption agents" for tirzepatide and semaglutide, noting that GLP-1 receptor agonists may reduce compulsive shopping, gambling, and other overconsumption behaviors driven by reward pathway dysfunction — alongside their established effects on food and substance cravings.

The Biological Argument

This is the same logic that makes the substance use disorder research biologically coherent. GLP-1 medications don't appear to target alcohol receptors or nicotine receptors specifically. They modulate the reward system at a more fundamental level. A slot machine activates the same dopamine pathway as a drink or a cigarette — just through different initial triggers.

The Counterargument: Dopamine Isn't Everything

There's a real risk in over-attributing every behavioral change to GLP-1's effect on dopamine. People who start losing weight often experience improved mood, increased energy, better sleep, and greater social engagement. These life improvements — completely independent of any neurochemical mechanism — could reduce gambling behavior simply by replacing it with more satisfying activities.

There's also a weight-loss-adjacent explanation: if someone is spending less time thinking about food (the "food noise" reduction), they may have more cognitive bandwidth for impulse control across all domains. This wouldn't require any direct effect on gambling circuitry — just a general improvement in executive function from reduced cognitive load.

What Would It Take to Know for Sure?

The evidence gap here is wide enough that the research community is still in the "interesting observation" phase. To move to confidence, we would need:

1. Systematic surveys of GLP-1 patients specifically asking about gambling and compulsive behaviors — not just recording what patients spontaneously volunteer.
2. Observational studies using insurance claims or EHR data to compare gambling disorder diagnoses in GLP-1 users versus matched controls (similar to the Wang/Volkow methodology for substances).
3. A randomized controlled trial in patients with diagnosed gambling disorder, measuring gambling frequency and severity with validated instruments like the Problem Gambling Severity Index (PGSI).

None of these exist yet. No trial for GLP-1 and gambling disorder is currently registered on ClinicalTrials.gov.

If you're already on a GLP-1 medication and notice reduced gambling urges, that's worth mentioning to your doctor. Your observation joins a growing body of reports that may eventually lead to formal research. But it shouldn't replace treatment for a condition that can cause serious financial and personal harm right now.